IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs

References

• Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25:1369-72; PMID:18066027; http://dx.doi.org/10.1038/nbt1207-1369
   PubMed Web of Science ®Google Scholar
• Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103
   PubMed Web of Science ®Google Scholar
• Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). Protein Eng Des Sel 2013; 26:589-98; PMID:23744091; http://dx.doi.org/10.1093/protein/gzt022
   PubMed Web of Science ®Google Scholar
• Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 2008; 45:3926-33; PMID:18691763; http://dx.doi.org/10.1016/j.molimm.2008.06.027
   PubMed Web of Science ®Google Scholar
• Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2:181-9; PMID:20150767; http://dx.doi.org/10.4161/mabs.2.2.11158
   PubMed Web of Science ®Google Scholar
• Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci U S A 2012; 109:6181-6; PMID:22474370; http://dx.doi.org/10.1073/pnas.1203954109
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
   PubMed Web of Science ®Google Scholar
• Kelton W, Mehta N, Charab W, Lee J, Lee CH, Kojima T, Kang TH, Georgiou G. IgGA: a “cross-isotype” engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem Biol 2014; 21:1603-9; PMID:25500223; http://dx.doi.org/10.1016/j.chembiol.2014.10.017
   PubMed Web of Science ®Google Scholar
• Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, Garber EA, Hess DM, Shapiro RI, Kenyon NS, Harlan DM, et al. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol 2004; 16:1583-94; PMID:15466914; http://dx.doi.org/10.1093/intimm/dxh162
   PubMed Web of Science ®Google Scholar
• Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279:6213-6; PMID:14699147; http://dx.doi.org/10.1074/jbc.C300470200
   PubMed Web of Science ®Google Scholar
• Li Q, Zeng M, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, et al. Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 2014; 193:3113-25; http://dx.doi.org/10.4049/jimmunol.1400820
   PubMed Web of Science ®Google Scholar
• Baruah K, Bowden TA, Krishna BA, Dwek RA, Crispin M, Scanlan CN. Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J Mol Biol 2012; 420:1-7; PMID:22484364; http://dx.doi.org/10.1016/j.jmb.2012.04.002
   PubMed Web of Science ®Google Scholar
• Bolton GR, Ackerman ME, Boesch AW. Separation of nonfucosylated antibodies with immobilized FcgammaRIII receptors. Biotechnol Prog 2013; 29:825-8; PMID:23554380; http://dx.doi.org/10.1002/btpr.1717
   PubMed Web of Science ®Google Scholar
• Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w
   PubMed Web of Science ®Google Scholar
• Imai-Nishiya H, Mori K, Inoue M, Wakitani M, Iida S, Shitara K, Satoh M. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 2007; 7:84; PMID:18047682; http://dx.doi.org/10.1186/1472-6750-7-84
   PubMed Web of Science ®Google Scholar
• Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. MAbs 2013; 5:229-36; PMID:23406628; http://dx.doi.org/10.4161/mabs.23452
   PubMed Web of Science ®Google Scholar
• Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306:151-60; PMID:16219319; http://dx.doi.org/10.1016/j.jim.2005.08.009
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
   PubMed Web of Science ®Google Scholar
• Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176-80; PMID:10052355; http://dx.doi.org/10.1038/6179
   PubMed Web of Science ®Google Scholar
• Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang LX. Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcgammaIIIa receptor. J Am Chem Soc 2011; 133:18975-91; http://dx.doi.org/10.1021/ja208390n
   PubMed Web of Science ®Google Scholar
• Mullard A. 2013 FDA drug approvals. Nat Rev Drug Discov 2014; 13:85-9; http://dx.doi.org/10.1038/nrd4239
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18:1395-403; PMID:22223529; http://dx.doi.org/10.1158/1078-0432.CCR-11-0850
   PubMed Web of Science ®Google Scholar
• Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, et al. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci 2011; 102:432-8; PMID:21205069; http://dx.doi.org/10.1111/j.1349-7006.2010.01809.x
   PubMed Web of Science ®Google Scholar
• Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20:685-91; PMID:19896358; http://dx.doi.org/10.1016/j.copbio.2009.10.011
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400; PMID:19369954; http://dx.doi.org/10.1038/nrmicro2129
   PubMed Web of Science ®Google Scholar
• Ehrlich PH, Harfeldt KE, Justice JC, Moustafa ZA, Ostberg L. Rhesus monkey responses to multiple injections of human monoclonal antibodies. Hybridoma 1987; 6:151-60; PMID:3494660; http://dx.doi.org/10.1089/hyb.1987.6.151
   PubMedGoogle Scholar
• Jonker M, van Lambalgen R, Mitchell DJ, Durham SK, Steinman L. Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies. J Autoimmun 1988; 1:399-414; PMID:3254183; http://dx.doi.org/10.1016/0896-8411(88)90064-9
   PubMed Web of Science ®Google Scholar
• Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Jr., Germond RL, Kampen RL, Patterson NB, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5:686-93; PMID:10371508; http://dx.doi.org/10.1038/9536
   PubMed Web of Science ®Google Scholar
• Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA. Monoclonal antibody to tumor necrosis factor–alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992; 120:574-88; PMID:1402333
   PubMed Web of Science ®Google Scholar
• Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, et al. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 2014; 88:8213-26; PMID:24829346; http://dx.doi.org/10.1128/JVI.01032-14
   PubMed Web of Science ®Google Scholar
• Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3:e9; PMID:17238286; http://dx.doi.org/10.1371/journal.ppat.0030009
   PubMed Web of Science ®Google Scholar
• Olinger GG, Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012; 109:18030-5; PMID:23071322; http://dx.doi.org/10.1073/pnas.1213709109
   PubMed Web of Science ®Google Scholar
• Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 2007; 104:9422-7; PMID:17517625; http://dx.doi.org/10.1073/pnas.0703498104
   PubMed Web of Science ®Google Scholar
• Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, Engle RE, Purcell RH. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 2007; 81:12766-74; PMID:17881450; http://dx.doi.org/10.1128/JVI.01420-07
   PubMed Web of Science ®Google Scholar
• Weltzin R, Traina-Dorge V, Soike K, Zhang JY, Mack P, Soman G, Drabik G, Monath TP. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 1996; 174:256-61; PMID:8699052; http://dx.doi.org/10.1093/infdis/174.2.256
   PubMed Web of Science ®Google Scholar
• Miyoshi-Akiyama T, Ishida I, Fukushi M, Yamaguchi K, Matsuoka Y, Ishihara T, Tsukahara M, Hatakeyama S, Itoh N, Morisawa A, et al. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. J Infect Dis 2011; 203:1574-81; PMID:21592986; http://dx.doi.org/10.1093/infdis/jir084
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-6; PMID:10655110; http://dx.doi.org/10.1038/72309
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-4; PMID:17805298; http://dx.doi.org/10.1038/nature06106
   PubMed Web of Science ®Google Scholar
• Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86:6189-96; PMID:22457527; http://dx.doi.org/10.1128/JVI.00491-12
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-10; PMID:10655111; http://dx.doi.org/10.1038/72318
   PubMed Web of Science ®Google Scholar
• Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343-6; PMID:12579198; http://dx.doi.org/10.1038/nm833
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-7; PMID:11483779; http://dx.doi.org/10.1128/JVI.75.17.8340-8347.2001
   PubMed Web of Science ®Google Scholar
• Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012; 109:18921-5; PMID:23100539; http://dx.doi.org/10.1073/pnas.1214785109
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-4; PMID:19525965; http://dx.doi.org/10.1038/nm.1974
   PubMed Web of Science ®Google Scholar
• Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-81; PMID:3277268; http://dx.doi.org/10.1126/science.3277268
   PubMed Web of Science ®Google Scholar
• Kontny U, Kurane I, Ennis FA. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol 1988; 62:3928-33; PMID:2459406
   PubMed Web of Science ®Google Scholar
• Nguyen DC, Scinicariello F, Attanasio R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 2011; 63:351-62; PMID:21327607; http://dx.doi.org/10.1007/s00251-011-0514-z
   PubMed Web of Science ®Google Scholar
• Chan YN, Boesch AW, Osei-Owusu NY, Emileh A, Crowley AR, Cocklin SL, Finstad SL, Linde CH, Howell RA, Zentner I, et al. IgG binding characteristics of rhesus macaque FcgammaR. J Immunol 2016; 197:2936-47; http://dx.doi.org/10.4049/jimmunol.1502252
   PubMed Web of Science ®Google Scholar
• Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, Heusser C. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol 2012; 188:4405-11; http://dx.doi.org/10.4049/jimmunol.1200090
   PubMed Web of Science ®Google Scholar
• Miller CJ, Genesca M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 2007; 81:5024-35; PMID:17329327; http://dx.doi.org/10.1128/JVI.02444-06
   PubMed Web of Science ®Google Scholar
• Sandilands GP, MacPherson SA, Burnett ER, Russell AJ, Downie I, MacSween RN. Differential expression of CD32 isoforms following alloactivation of human T cells. Immunology 1997; 91:204-11; PMID:9227318; http://dx.doi.org/10.1046/j.1365-2567.1997.00241.x
   PubMed Web of Science ®Google Scholar
• Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996; 157:541-8.
   PubMed Web of Science ®Google Scholar
• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012; 11:311-31; PMID:22460124; http://dx.doi.org/10.1038/nrd2909
   PubMed Web of Science ®Google Scholar
• Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, et al. Polymorphisms and interspecies differences of the activating and inhibitory FcgammaRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol 2014; 192:792-803; http://dx.doi.org/10.4049/jimmunol.1301554
   PubMed Web of Science ®Google Scholar
• Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, Stan R, Croce K, Mayadas TN. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood 2012; 120:4421-31; PMID:22955924; http://dx.doi.org/10.1182/blood-2011-12-401133
   PubMed Web of Science ®Google Scholar
• Behnen M, Leschczyk C, Moller S, Batel T, Klinger M, Solbach W, Laskay T. Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcgammaRIIIB and Mac-1. J Immunol 2014; 193:1954-65 ; http://dx.doi.org/10.4049/jimmunol.1400478
   PubMed Web of Science ®Google Scholar
• Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K, Satoh M. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009; 37:309-21; PMID:19218011; http://dx.doi.org/10.1016/j.exphem.2008.11.006
   PubMed Web of Science ®Google Scholar
• Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M. Increasing FcgammaRIIa affinity of an FcgammaRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs 2014; 6:409-21; PMID:24492248; http://dx.doi.org/10.4161/mabs.27457
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25; PMID:19018092; http://dx.doi.org/10.1182/blood-2008-09-179754
   PubMed Web of Science ®Google Scholar
• Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, Powell MS, Tan PS, Cendron AC, Wines BD, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011; 187:3208-17; http://dx.doi.org/10.4049/jimmunol.1101467
   PubMed Web of Science ®Google Scholar
• Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; http://dx.doi.org/10.1038/35018508
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Nimmerjahn F. Antibody Fc: linking adaptive and innate immunity. Amsterdam, Burlington: Elsevier/Academic Press, 2014.
   Google Scholar
• Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669-74; PMID:21768335; http://dx.doi.org/10.1073/pnas.1108455108
   PubMed Web of Science ®Google Scholar
• Boesch AW, Brown EP, Cheng HD, Ofori MO, Normandin E, Nigrovic PA, Alter G, Ackerman ME. Highly parallel characterization of IgG Fc binding interactions. MAbs 2014; 6:915-27; PMID:24927273; http://dx.doi.org/10.4161/mabs.28808
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/cwl057
   PubMed Web of Science ®Google Scholar
• Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914-23; PMID:16167082; http://dx.doi.org/10.1172/JCI24772
   PubMed Web of Science ®Google Scholar
• Rogers KA, Scinicariello F, Attanasio R. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. Journal of immunology 2006; 177:3848-56; http://dx.doi.org/10.4049/jimmunol.177.6.3848
   PubMed Web of Science ®Google Scholar
• Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 2013; 5:872-81; PMID:23995614; http://dx.doi.org/10.4161/mabs.26307
   PubMed Web of Science ®Google Scholar
• Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA. Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. Immunology 2008; 124:215-22; PMID:18201184; http://dx.doi.org/10.1111/j.1365-2567.2007.02757.x
   PubMed Web of Science ®Google Scholar
• Furness AJ, Vargas FA, Peggs KS, Quezada SA. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014; 35:290-8; PMID:24953012; http://dx.doi.org/10.1016/j.it.2014.05.002
   PubMed Web of Science ®Google Scholar
• Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; 161:512-26; PMID:20880392; http://dx.doi.org/10.1111/j.1476-5381.2010.00922.x
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260-3; PMID:24626930; http://dx.doi.org/10.1126/science.1248943
   PubMed Web of Science ®Google Scholar
• van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, FcgammaRI. J Immunol 2011; 186:2699-704; http://dx.doi.org/10.4049/jimmunol.1003526
   PubMed Web of Science ®Google Scholar
• de Lange GG. Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogenet 1989; 6:7-17; PMID:2698222
   PubMedGoogle Scholar
• Kumpel BM, Wiener E, Urbaniak SJ, Bradley BA. Human monoclonal anti-D antibodies. II. The relationship between IgG subclass, Gm allotype and Fc mediated function. Br J Haematol 1989; 71:415-20; http://dx.doi.org/10.1111/j.1365-2141.1989.tb04300.x
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108:3573-9; PMID:16849638; http://dx.doi.org/10.1182/blood-2006-05-024539
   PubMed Web of Science ®Google Scholar
• Neuber T, Frese K, Jaehrling J, Jager S, Daubert D, Felderer K, Linnemann M, Hohne A, Kaden S, Kolln J, et al. Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs 2014; 6:928-42; PMID:24802048; http://dx.doi.org/10.4161/mabs.28744
   PubMed Web of Science ®Google Scholar
• Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, et al. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs 2014; 6:422-36; PMID:24492301; http://dx.doi.org/10.4161/mabs.27854
   PubMed Web of Science ®Google Scholar
• Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog 2015; 11:e1005042; PMID:26237403; http://dx.doi.org/10.1371/journal.ppat.1005042
   PubMed Web of Science ®Google Scholar
• Sestak K, Scheiners C, Wu XW, Hollemweguer E. Identification of anti-human CD antibodies reactive with rhesus macaque peripheral blood cells. Vet Immunol Immunopathol 2007; 119:21-6; PMID:17681612; http://dx.doi.org/10.1016/j.vetimm.2007.06.011
   PubMed Web of Science ®Google Scholar
• Carter DL, Shieh TM, Blosser RL, Chadwick KR, Margolick JB, Hildreth JE, Clements JE, Zink MC. CD56 identifies monocytes and not natural killer cells in rhesus macaques. Cytometry 1999; 37:41-50; PMID:10451505; http://dx.doi.org/10.1002/(SICI)1097-0320(19990901)37:1%3c41::AID-CYTO5%3e3.0.CO;2-4
   PubMedGoogle Scholar
• O'Doherty U, Ignatius R, Bhardwaj N, Pope M. Generation of monocyte-derived dendritic cells from precursors in rhesus macaque blood. J Immunol Methods 1997; 207:185-94; PMID:9368645; http://dx.doi.org/10.1016/S0022-1759(97)00119-1
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-61; PMID:20616233; http://dx.doi.org/10.1126/science.1187659
   PubMed Web of Science ®Google Scholar